NCT02246049View on ClinicalTrials.gov

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

PHASE2CompletedINTERVENTIONAL

Enrollment

69

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

5-fluorouracil

Given IV

DRUG

Irinotecan hydrochloride

Given IV

DRUG

Leucovorin calcium

Given IV

DRUG

Oxaliplatin

Given IV

Trial Locations (1)

162-0814

EPS Corporation, Shinjuku

Sponsors

Lead Sponsor

EPS Corporation

All Listed Sponsors

lead

EPS Corporation

OTHER